CoChat

Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond

Vallazza, Britta, Petri, Sebastian, Poleganov, Marco A., Eberle, Florian, Kuhn, Andreas N., Sahin, Ugur · 2015 · WIREs RNA
Cited by 72

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

In recent years, the interest in using messenger RNA (mRNA) as a therapeutic means to tackle different diseases has enormously increased. This holds true not only for numerous preclinical studies, but mRNA has also entered the clinic to fight cancer. The advantages of using mRNA compared to DNA were recognized very early on, e.g., the lack of risk for genomic integration, or the expression of the encoded protein in the cytoplasm without the need to cross the nuclear membrane. However, it was generally assumed that mRNA is just not stable enough to give rise to sufficient expression of the encoded protein. Yet, an initially small group of mRNA aficionados could demonstrate that the stability of mRNA and the efficiency, by which the encoded protein is translated, can be significantly increased by selecting the right set of cis‐acting structural elements (including the 5′‐cap, 5′‐ and 3′‐untranslated regions, poly(A)‐tail, and modified building blocks). In parallel, significant advances in RNA packaging and delivery have been made, extending the potential for this molecule. This paved the way for further work to prove mRNA as a promising therapeutic for multiple diseases. Here, we review the developments to optimize mRNA regarding stability, translational efficiency, and immune‐modulating properties to enhance its functionality and efficacy as a therapeutic. Furthermore, we summarize the current status of preclinical and clinical studies that use mRNA for cancer immunotherapy, for the expression of functional proteins as so‐called transcript (or protein) replacement therapy, as well as for induction of pluripotent stem cells. WIREs RNA 2015, 6:471–499. doi: 10.1002/wrna.1288 This article is categorized under: Translation > Translation Regulation RNA Turnover and Surveillance > Turnover/Surveillance Mechanisms RNA in Disease and Development > RNA in Disease

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/wrna.1288

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Research works printed but not linked: 243

  1. 10.1016/S0092-8674(00)81517-2 · DOI · Paper page
  2. 10.1128/MCB.7.9.3268 · DOI · Paper page
  3. 10.1016/j.cell.2009.01.042 · DOI · Paper page
  4. 10.1002/wrna.40 · DOI · Paper page
  5. 10.1128/MCB.24.12.5521-5533.2004 · DOI
  6. 10.1038/nsmb1016 · DOI · Paper page
  7. 10.1016/S0092-8674(01)00225-2 · DOI · Paper page
  8. 10.1016/S0021-9258(19)37166-2 · DOI · Paper page
  9. 10.1016/S1097-2765(00)80442-6 · DOI · Paper page
  10. 10.1074/jbc.M102270200 · DOI · Paper page
  11. 10.1093/emboj/21.6.1427 · DOI · Paper page
  12. Li Y, 2010, Regulation of mRNA decapping, WlREs RNA, 1, 253
  13. Ling SH, 2011, Structural and functional insights into eukaryotic mRNA decapping, WlREs RNA, 2, 193
  14. 10.1073/pnas.192445599 · DOI · Paper page
  15. 10.1038/nsmb.1984 · DOI · Paper page
  16. Nagarajan VK, 1829, XRN 5′‐‐>3′ exoribonucleases: structure, mechanisms and functions, Biochim Biophys Acta, 2013, 590
  17. 10.1038/nrm1964 · DOI · Paper page
  18. 10.4161/rna.8.1.14237 · DOI · Paper page
  19. 10.1093/emboj/cdf448 · DOI · Paper page
  20. Schoenberg DR, 2011, Mechanisms of endonuclease‐mediated mRNA decay, WlREs RNA, 2, 582
  21. 10.1038/nrg2290 · DOI
  22. Schweingruber C, 1829, Nonsense‐mediated mRNA decay—mechanisms of substrate mRNA recognition and degradation in mammalian cells, Biochim Biophys Acta, 2013, 612
  23. Martin SA, 1975, Modification of RNA by mRNA guanylyltransferase and mRNA (guanine‐7‐)methyltransferase from vaccinia virions, J Biol Chem, 250, 9330, 10.1016/S0021-9258(19)40647-9 · DOI · Paper page
  24. 10.1016/0076-6879(89)80090-4 · DOI
  25. Pasquinelli AE, 1995, Reverse 5' caps in RNAs made in vitro by phage RNA polymerases, RNA, 1, 957
  26. 10.1261/rna.5430403 · DOI · Paper page
  27. Kore AR, 2010, Synthesis and evaluation of 2'‐O‐allyl substituted dinucleotide cap analog for mRNA translation, Bioorg Med Chem, 18, 8061, 10.1016/j.bmc.2010.09.013 · doi:10.1016/j.bmc.2010.09.013
  28. Kore AR, 2007, Synthesis and application of 2'‐fluoro‐substituted cap analogs, Bioorg Med Chem Lett, 17, 5295, 10.1016/j.bmcl.2007.08.029 · doi:10.1016/j.bmcl.2007.08.029
  29. 10.1021/ja901655p · DOI · Paper page
  30. Kore AR, 2008, Synthesis and application of a new 2′,3′‐isopropylidene guanosine substituted cap analog, Bioorg Med Chem Lett, 18, 4828, 10.1016/j.bmcl.2008.07.075 · DOI
  31. 10.1021/ol0167715 · DOI · Paper page
  32. Stepinski J, 2001, Synthesis and properties of mRNAs containing the novel "anti‐reverse" cap analogs 7‐methyl(3'‐O‐methyl)GpppG and 7‐methyl (3'‐deoxy)GpppG, RNA, 7, 1486
  33. 10.1016/j.bbrc.2005.12.105 · DOI · Paper page
  34. 10.1261/rna.701307 · DOI · Paper page
  35. 10.1016/j.bmc.2005.12.045 · DOI
  36. 10.1016/j.bmc.2013.05.041 · DOI
  37. Kowalska J, 2008, The first examples of mRNA cap analogs bearing boranophosphate modification, Nucleic Acids Symp Ser (Oxf), 52, 289, 10.1093/nass/nrn146 · DOI
  38. 10.1016/j.bmc.2012.01.013 · DOI
  39. 10.1039/b911347a · DOI
  40. 10.1039/b9nj00644c · DOI · Paper page
  41. 10.1261/rna.2430711 · DOI
  42. 10.1016/j.bmcl.2013.05.001 · DOI
  43. 10.1074/jbc.M509121200 · DOI · Paper page
  44. Benteyn D, 2013, Characterization of CD8+ T‐cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC‐MEL), Biomed Res Int, 2013, 976383, 10.1155/2013/976383 · DOI · Paper page
  45. 10.1186/1479-5876-12-175 · DOI
  46. 10.1146/annurev.cellbio.14.1.399 · DOI · Paper page
  47. 10.1016/S0021-9258(18)54860-2 · DOI · Paper page
  48. Velden AW, 2001, Vector design for optimal protein expression, Biotechniques, 31
  49. 10.1128/MCB.01445-06 · DOI · Paper page
  50. 10.1016/j.gde.2011.03.002 · DOI · Paper page
  51. 10.1073/pnas.94.6.2410 · DOI · Paper page
  52. 10.1177/153537020322800409 · DOI · Paper page
  53. 10.1128/MCB.26.6.2419-2429.2006 · DOI
  54. 10.1186/1479-0556-3-6 · DOI · Paper page
  55. 10.4049/jimmunol.180.1.309 · DOI · Paper page
  56. 10.4049/jimmunol.164.10.5508 · DOI · Paper page
  57. 10.1046/j.1432-1327.2001.02064.x · DOI · Paper page
  58. 10.1016/j.bbrc.2010.02.150 · DOI · Paper page
  59. 10.1016/j.gene.2006.12.013 · DOI
  60. 10.1016/j.tig.2012.07.006 · DOI · Paper page
  61. 10.1038/nrg2899 · DOI · Paper page
  62. 10.1038/mt.2012.29 · DOI · Paper page
  63. 10.1371/journal.pone.0017596 · DOI · Paper page
  64. 10.1089/jir.2005.25.1 · DOI · Paper page
  65. 10.1186/gb-2005-6-9-r75 · DOI · Paper page
  66. 10.1371/journal.pone.0038864 · DOI
  67. 10.1038/sj.gt.3302874 · DOI
  68. 10.1007/s00262-008-0556-8 · DOI
  69. 10.1016/j.clim.2005.12.009 · DOI · Paper page
  70. 10.1097/01.cji.0000210385.48327.1e · DOI
  71. 10.1182/blood-2005-01-0339 · DOI · Paper page
  72. 10.1038/mtna.2013.54 · DOI · Paper page
  73. 10.1002/biot.201000332 · DOI · Paper page
  74. 10.1073/pnas.89.21.10380 · DOI · Paper page
  75. Martin G, 1998, Tailing and 3'‐end labeling of RNA with yeast poly(A) polymerase and various nucleotides, RNA, 4, 226
  76. Boczkowski D, 2000, Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells, Cancer Res, 60, 1028
  77. 10.1017/S1355838298980669 · DOI · Paper page
  78. Peng J, 2005, mRNA with a <20‐nt poly(A) tail imparted by the poly(A)‐limiting element is translated as efficiently in vivo as long poly(A) mRNA, RNA, 11, 1131, 10.1261/rna.2470905 · DOI · Paper page
  79. 10.1089/hum.2006.17.1027 · DOI · Paper page
  80. 10.1186/1471-2199-9-90 · DOI · Paper page
  81. 10.1016/j.cbpa.2006.10.001 · DOI · Paper page
  82. Aurup H, 1994, Translation of 2'‐modified mRNA in vitro and in vivo, Nucleic Acids Res, 22, 4963, 10.1093/nar/22.23.4963 · doi:10.1093/nar/22.23.4963
  83. 10.1002/asia.200800370 · DOI
  84. 10.1021/ja801389n · DOI
  85. 10.1021/bi962674l · DOI · Paper page
  86. 10.1093/nar/15.10.4145 · DOI
  87. 10.1016/S0076-6879(00)17006-5 · DOI
  88. 10.1002/1439-7633(20010302)2:3<212::AID-CBIC212>3.0.CO;2-R · DOI · Paper page
  89. 10.1073/pnas.0809506106 · DOI · Paper page
  90. 10.1021/bi000579d · DOI
  91. 10.1074/jbc.273.21.13170 · DOI
  92. 10.1093/nar/gkq638 · DOI
  93. 10.1261/rna.1862210 · DOI · Paper page
  94. 10.1261/rna.038117.113 · DOI
  95. 10.1038/nprot.2007.480 · DOI
  96. Anderson AC, 1996, HPLC purification of RNA for crystallography and NMR, RNA, 2, 110
  97. 10.1261/rna.528007 · DOI · Paper page
  98. 10.1006/abio.1999.4030 · doi:10.1006/abio.1999.4030
  99. 10.1016/j.jpba.2012.04.031 · doi:10.1016/j.jpba.2012.04.031
  100. 10.1002/elps.200600673 · DOI
  101. 10.1016/j.ab.2009.01.040 · doi:10.1016/j.ab.2009.01.040
  102. 10.1016/j.ijpharm.2010.01.019 · DOI · Paper page
  103. 10.1006/jsre.2002.6435 · DOI
  104. 10.1111/j.1365-2567.2008.02833.x · DOI
  105. 10.1089/hum.2008.068 · DOI · Paper page
  106. 10.1038/sj.leu.2403463 · DOI
  107. 10.1007/s10544-010-9440-3 · DOI
  108. 10.1038/cgt.2009.61 · DOI · Paper page
  109. 10.1016/j.jconrel.2006.06.024 · DOI · Paper page
  110. 10.1111/j.1476-5381.2009.00288.x · DOI · Paper page
  111. 10.3109/1061186X.2010.504262 · DOI · Paper page
  112. 10.1007/978-1-62703-260-5_16 · DOI · Paper page
  113. 10.1002/0471142301.ns0422s57 · DOI
  114. Galla M, 2013, Retrovirus‐based mRNA transfer for transient cell manipulation, Methods Mol Biol, 969, 139, 10.1007/978-1-62703-260-5_10 · DOI
  115. 10.3390/v1010013 · DOI · Paper page
  116. 10.1074/jbc.M110.183780 · DOI · Paper page
  117. 10.1093/nar/gkr384 · DOI
  118. 10.1016/j.molcel.2004.09.023 · DOI
  119. 10.1016/j.tibtech.2009.02.002 · DOI
  120. 10.1038/mt.2010.298 · DOI
  121. 10.1172/JCI0214364 · DOI · Paper page
  122. 10.1016/j.coi.2011.03.007 · DOI
  123. 10.1097/00000658-200204000-00013 · DOI · Paper page
  124. 10.1038/gt.2011.17 · DOI · Paper page
  125. 10.4161/rna.8.4.15394 · DOI · Paper page
  126. 10.1002/eji.200425656 · DOI · Paper page
  127. 10.1038/35047123 · DOI · Paper page
  128. 10.1126/science.1093620 · DOI · Paper page
  129. 10.1002/eji.200636617 · DOI · Paper page
  130. 10.4049/jimmunol.177.11.8164 · DOI · Paper page
  131. 10.1146/annurev.immunol.23.021704.115633 · DOI · Paper page
  132. 10.1038/nature04517 · DOI · Paper page
  133. Kariko K, 2007, Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development, Curr Opin Drug Discov Devel, 10, 523
  134. 10.1038/35099560 · DOI · Paper page
  135. 10.1128/JVI.00935-08 · DOI · Paper page
  136. 10.1038/nature06765 · DOI · Paper page
  137. 10.1038/nature04734 · DOI · Paper page
  138. 10.1126/science.1132505 · DOI · Paper page
  139. 10.1084/jem.20080091 · DOI · Paper page
  140. 10.1016/S0968-0004(00)01580-2 · DOI · Paper page
  141. 10.1021/bi061531o · DOI
  142. 10.1038/nature09489 · DOI · Paper page
  143. 10.1038/nsmb.1863 · DOI · Paper page
  144. 10.1371/journal.ppat.1003663 · DOI · Paper page
  145. 10.1128/JVI.00883-13 · DOI
  146. 10.1084/jem.184.2.465 · DOI · Paper page
  147. 10.1080/14653240902960411 · DOI
  148. 10.1073/pnas.1008051107 · DOI · Paper page
  149. 10.1002/(SICI)1097-0215(19990702)82:1<121::AID-IJC20>3.0.CO;2-X · DOI · Paper page
  150. Lesterhuis WJ, 2010, Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients, Anticancer Res, 30, 5091
  151. Coosemans A, 2010, Immunological response after therapeutic vaccination with WT1 mRNA‐loaded dendritic cells in end‐stage endometrial carcinoma, Anticancer Res, 30, 3709
  152. 10.1007/s00262-013-1453-3 · DOI · Paper page
  153. Berneman ZN, 2014, Dendritic cell vaccination in malignant pleural mesothelioma: a phase I/II study, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.7583 · DOI
  154. 10.1158/1078-0432.CCR-11-3368 · DOI · Paper page
  155. 10.1016/j.ajo.2014.07.014 · DOI
  156. 10.1158/1078-0432.CCR-08-2982 · DOI · Paper page
  157. 10.1172/JCI67544 · DOI
  158. 10.1038/sj.cgt.7700961 · DOI · Paper page
  159. Neyns B, 2012, Phase IB study on combined intradermal (ID) and intravenous (IV) administration of autologous mRNA electroporated dendritic cells (DC) as a single‐agent cellular immunotherapy or combined with ipilimumab, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.2507 · doi:10.1200/jco.2012.30.15_suppl.2507
  160. Neyns B, 2014, Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC‐MEL) in combination with ipilimumab in patients with pretreated advanced melanoma, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.3014 · doi:10.1200/jco.2014.32.15_suppl.3014
  161. 10.1158/0008-5472.CAN-08-3920 · DOI
  162. 10.1007/s00262-011-1176-2 · DOI
  163. 10.1097/CJI.0b013e31821dcb31 · DOI · Paper page
  164. 10.1093/annonc/mdt245 · DOI · Paper page
  165. 10.1007/s00262-014-1642-8 · DOI
  166. 10.1007/s00262-013-1438-2 · DOI
  167. Imhof M, 2013, Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study, J Clin Oncol, 31, 10.1200/jco.2013.31.15_suppl.3052 · doi:10.1200/jco.2013.31.15_suppl.3052
  168. 10.1016/S1470-2045(07)70142-0 · DOI
  169. Coosemans A, 2013, Immunological response after WT1 mRNA‐loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma, Anticancer Res, 33, 3855
  170. 10.1007/s00262-011-0991-9 · DOI
  171. 10.1385/IJGC:32:1:1 · DOI
  172. 10.1038/sj.bjc.6602761 · DOI · Paper page
  173. Su Z, 2003, Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA‐transfected dendritic cells, Cancer Res, 63, 2127
  174. 10.1172/JCI25947 · DOI · Paper page
  175. Healey D, 2010, Immunomonitoring of a phase I/II study of AGS‐003, a dendritic cell immunotherapeutic, as first‐line treatment for metastatic renal cell carcinoma, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.e13006 · doi:10.1200/jco.2010.28.15_suppl.e13006
  176. Amin A, 2014, Long‐term survival in unfavorable‐risk mRCC patients treated with a combination of autologous immunotherapy (AGS‐003) plus sunitinib, J Clin Oncol, 32, 10.1200/jco.2014.32.15_suppl.4524 · DOI
  177. Willemen Y, 2012, Open label phase I/II study of Wilms' tumor gene 1 (WT1) mRNA‐transfected autologous dendritic cell vaccination in patients with solid tumors, J Clin Oncol, 30, 10.1200/jco.2012.30.15_suppl.e13051 · doi:10.1200/jco.2012.30.15_suppl.e13051
  178. Coosemans A, 2013, Wilms' tumor gene 1 (WT1)‐‐loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial, Anticancer Res, 33, 5495
  179. 10.1186/1471-2407-14-748 · DOI · Paper page
  180. Kübler H, 2011, Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self‐adjuvanted mRNA, J Clin Oncol, 29, 10.1200/jco.2011.29.15_suppl.4535 · DOI · Paper page
  181. 10.1038/mt.2010.289 · DOI · Paper page
  182. 10.1158/2326-6066.CIR-13-0022 · DOI · Paper page
  183. 10.1158/0008-5472.CAN-11-3722 · DOI · Paper page
  184. 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-# · doi:10.1002/1521-4141(200001)30:1<1::aid-immu1>3.0.co;2-#
  185. 10.1016/j.clim.2011.10.010 · DOI
  186. 10.1016/j.clim.2009.09.009 · DOI · Paper page
  187. 10.1097/TP.0000000000000272 · DOI · Paper page
  188. 10.1097/QAD.0b013e32834f33e8 · DOI · Paper page
  189. 10.2174/156652311796150390 · DOI · Paper page
  190. 10.1038/nri841 · DOI · Paper page
  191. 10.2174/156652309789753338 · DOI
  192. 10.1038/nbt.2938 · DOI · Paper page
  193. 10.1158/2326-6066.CIR-14-0108 · DOI · Paper page
  194. 10.2174/156652310791111001 · doi:10.2174/156652310791111001
  195. Clay TM, 1999, Efficient transfer of a tumor antigen‐reactive TCR to human peripheral blood lymphocytes confers anti‐tumor reactivity, J Immunol, 163, 507, 10.4049/jimmunol.163.1.507 · DOI · Paper page
  196. 10.1038/ni1001-957 · DOI · Paper page
  197. 10.1182/blood-2009-03-211714 · DOI · Paper page
  198. 10.1038/mt.2010.272 · DOI · Paper page
  199. 10.1200/JCO.2010.32.2537 · DOI · Paper page
  200. 10.1126/scitranslmed.3002842 · DOI · Paper page

200 of 243 shown

Cited by

See all 72

Metadata

Authors
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Sahin, U.
Venue
WIREs RNA
Publisher
Wiley
Published
2015-06-09
Volume
6
Issue
5
Pages
471-499
ISSN
  • 1757-7004 (ISSN-L)
  • 1757-7012
OpenAlex
W1518058088
Cited by
72
References
66
FWCI
0.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. https://app.cochat.ai/papers/10.1002/wrna.1288
The paper
Vallazza, B., Petri, S., Poleganov, M. A., Eberle, F., Kuhn, A. N., & Sahin, U. (2015). Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. WIREs RNA. https://doi.org/10.1002/wrna.1288

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.